Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Inclusion criteria

• Adult subjects ≥ 18 to ≤ 55 years of age
• Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm
• Body mass index (BMI) ≥18 and ≤35 kg/sq m
• Willing and able to provide written informed consent

Exclusion criteria

• Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing
• Use of any investigational agent or study treatment within 30 days of dosing
• Use of any protein or antibody-based therapeutic agents within 3 months of Screening
• Prior exposure to LX4211
• Use of cigarettes or any tobacco products within 2 months prior to Screening and while participating in the study
• History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption
• History of any major surgery within 6 months of Screening
• History of any hypersensitivity to the inactive components of LX4211
• History of renal disease or significantly abnormal kidney function tests
• History of hepatic disease or significantly abnormal liver function tests
• History of any active infection within 14 days prior to Day 1
• History of alcohol or substance abuse within 2 years prior to Day 1
• Donation or loss of >400 mL of blood or blood product within 3 months of dosing
• Positive urine glucose at Screening
• Positive urine screen for drugs of abuse, or urine test for alcohol at Screening or Day -1
• Inability or difficulty swallowing pills
• Unable or unwilling to communicate or cooperate with the Investigator